🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pts in long-term remission show significant recovery of the gut microbial ecosystem w/ high species diversity & composition. The presence of A. muciniphila predicted flare-free outcomes. Read more here: bit.ly/3R7lCu7

In #Octave open, #UC pts w/ long-term maintenance therapy with tofacitinib 5 or 10 mg BD can sustain beneficial effects on #HRQoL for up to 72 months, regardless of prior remission or responder status, or Rx history. David T. Rubin, MD bit.ly/3MTPVmx

Could transplanted human intestinal organoids developed in vitro & expanded into healthy stem cells promote epithelial regeneration & restore intestinal physiology? Could these be useful in tissue repair in a defined #IBD group? Learn from Gwo Tzer bit.ly/40ISXzT

In a nationwide Danish cohort of 30,102 patients with #IBD and (+) Covid-19 PCR test by Bente Mertz Nørgård, no increased #corticosteroid prescriptions were noted. Patients can be counseled that #COVID-19 does not trigger #IBD flare-ups. bit.ly/3Ga41wu

x.com/CrohnsColitisF…

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis:... sciencedirect.com/science/articl…

Should we push further in T2T paradigm to achieve histologic remission? According to this study - yes! 445 patients with UC and Mayo 0 or 1 endoscopic activity, histologic activity was a significant predictor of clinical relapse 🤒 Raymond Cross bit.ly/3RL1nDP

Important mechanistic insight into cancer pathways in UC. 🔥 cytokines ⬇️ miR-615-5p, which ⬆️ STC1, promoting tumorigenesis bit.ly/3vQdtms

Meet our 2024 IBDJournal & CC360 Social Media Team! Ben Click Maia Kayal MD Shivi S Siva M.D. aka Shivi S. Sivanantham Shrinivas Bishu Jeffrey M Dueker, MD, MPH Simon Hong Suha Abushamma, MD

How do you compare IBD therapies without H2H trials 🤔? In this study, Matching-Adjusted Indirect Comparison is used to compare filgotinib vs VDZ, TOF, UST for UC bit.ly/3Ikjafw

In 600 pts w/ #CD, the overall prevalance of fecal incontinence (FI) was 22.3%. Risk factors for FI were penetrating dz, age at dx, perianal dz at dx, and ⬆️ Perianal Disease Activity Index score. These can be used for early risk prediction of FI in #CD💩 bit.ly/3TDzKxD

IUS in IBD is great tech, but problem is standardization 🤔 This piece by Phillip Gu Dan Carter Dr Dermot McGovern Jason H. Moore, PhD et al. shows the promise of radiomics over traditional neural network AI models ⚠️ limitation is single center/operator doi.org/10.1093/crocol…

This is Shivi S. Siva @sivashivi. I’m an academic #IBD specialist Montefiore Gastroenterology. I'm back authoring tweets for @IBDjournals in October 2024. Calling all patients with and providers treating IBD to follow along to encourage a great dialogue on #Crohns #UC

A retrospective study of 202 #CD/pts Virginia Solitano, showed 22% had endoscopic skipping prox/to TI & 25% smallbowel skip lesions, ID by #CTE/MRE. Imaging ID #stricturing dz in 36.2% /pts missed by #ileoscopy. Ileoscopy missed active CD in prox.bowel, in 1/5 of pts, ID by imaging.

In 10,578 #IBD pts Ellen Zimmermann, show improved access to care in Hispanic pts & use of higher #biologics than non-Hispanic White (NHW) OR: 1.3, P < .0001. Non-Hispanic Black /pts used more steroids than NHW OR: 1.2, P = .0004 w/higher ER visits & hosp/to NHW. doi.org/10.1093/ibd/iz…

IUS is performed in office w/RT #CD dz activity, w/swift Rx changes. Parades et al. provide an external validation of the simple IUS score for #CD, w/good correlation w/endoscopy (SES-CD r = .757, P < .001). Should IUS be a 1st line tool for f/u in #CD? doi.org/10.1093/ibd/iz…

Could gut microbiome act as a predictive biomarker to identify#IBD pts in risk of Dz progression & intensify Rx? Ranko Gacesa show by whole-genome metagenomics on basal fecal samples & a 10 year retrospective analysis of pts EMR, personalized Rx is feasible. doi.org/10.1093/ibd/iz…

Peter Higgins reports that socially vulnerable patients w#IBD are more likely to be diagnosed w/# depression but not anxiety. Overall rates of screening for depression and anxiety are low, particularly among more socially vulnerable patients. Find out more doi.org/10.1093/ibd/iz…

I know I’m a bit late, but here’s the updated table of #IBD treatments with their doses & routes of administration with the addition of guselkumab Full quality table➡️ ibd-eii.com/ibdcheatsheet/

Meet our 2025 IBDJournal & CC360 Social Media Team, who have already been hard at work! 👏 Stay tuned each month for perspectives on the latest science published in @IBDjournals from each of these #IBD physicians. 🔬📊 Ben Click Shivi S Siva M.D. aka Shivi S. Sivanantham Jeffrey M Dueker, MD, MPH Simon Hong Suha Abushamma, MD